Pediatric Tuberculosis Research and Development: Progress, Priorities and Funding Opportunities

Lindsay McKenna; Ani Herna Sari; Sushant Mane; Anna Scardigli; Grania Brigden; Vanessa Rouzier; Mercedes C Becerra; Anneke C Hesseling; Farhana Amanullah

doi:10.3390/pathogens11020128

Pediatric Tuberculosis Research and Development: Progress, Priorities and Funding Opportunities

Pathogens. 2022 Jan 21;11(2):128. doi: 10.3390/pathogens11020128.

Authors

Lindsay McKenna¹, Ani Herna Sari², Sushant Mane³, Anna Scardigli⁴, Grania Brigden⁴, Vanessa Rouzier⁵, Mercedes C Becerra⁶, Anneke C Hesseling⁷, Farhana Amanullah⁸

Affiliations

¹ Treatment Action Group, TB Project, New York, NY 10004, USA.
² Global TB Community Advisory Board (TB CAB), Social Science Student at Airlangga University, Surabaya 60286, Indonesia.
³ State Pediatric Centre of Excellence for Tuberculosis, Department of Pediatrics, Grant Government Medical College, Sir J.J. Group of Hospitals, Mumbai 400008, India.
⁴ The Global Fund to Fight AIDS, Tuberculosis and Malaria, 1218 Geneva, Switzerland.
⁵ Department of Pediatrics, GHESKIO Centers, Port-au-Prince HT-6110, Haiti.
⁶ Department of Global Health and Social Medicine, Harvard Medical School, Boston, MA 02115, USA.
⁷ Desmond Tutu TB Centre, Stellenbosch University, Cape Town Stellenbosch 7600, South Africa.
⁸ Department of Pediatrics, The Indus Hospital and Health Network, The Aga Khan University Hospital, Karachi 75500, Pakistan.

Abstract

In this article, we highlight technological pediatric TB research advances across the TB care cascade; discuss recently completed or ongoing work in adults and corresponding significant research gaps for children; and offer recommendations and opportunities to increase investments and accelerate pediatric TB R&D.

Keywords: R&D; innovation; pediatric TB; research and development.